{"id":"NCT02611830","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-18","primaryCompletion":"2018-05-30","completion":"2018-08-21","firstPosted":"2015-11-23","resultsPosted":"2020-01-23","lastUpdate":"2022-05-25"},"enrollment":383,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Colitis, Ulcerative"],"interventions":[{"type":"DRUG","name":"Vedolizumab 300 mg IV","otherNames":[]},{"type":"DRUG","name":"Placebo IV","otherNames":[]},{"type":"DRUG","name":"Vedolizumab 108 mg SC","otherNames":[]},{"type":"DRUG","name":"Placebo SC","otherNames":[]}],"arms":[{"label":"Maintenance Phase: Induction IV + Vedolizumab 108 mg SC","type":"EXPERIMENTAL"},{"label":"Maintenance Phase: Induction IV + Vedolizumab 300 mg IV","type":"EXPERIMENTAL"},{"label":"Maintenance Phase: Induction IV + Placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) maintenance treatment on clinical remission at Week 52 in participants with moderately to severely active ulcerative colitis (UC) who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.","primaryOutcome":{"measure":"Percentage of Participants Achieving Clinical Remission at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Maintenance Phase: Induction IV + Placebo","deltaMin":14.3,"sd":null},{"arm":"Maintenance Phase: Induction IV + Vedolizumab 108 mg SC","deltaMin":46.2,"sd":null},{"arm":"Maintenance Phase: Induction IV + Vedolizumab 300 mg IV","deltaMin":42.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":174,"countries":["United States","Argentina","Australia","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Croatia","Czechia","Denmark","Estonia","Germany","Hungary","Israel","Italy","Japan","Lithuania","Mexico","Netherlands","Poland","Romania","Russia","Serbia","Slovakia","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38417060","32806876","31470005"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":167},"commonTop":["Colitis ulcerative","Nasopharyngitis","Anaemia","Headache","Upper respiratory tract infection"]}}